WALTHAM, Mass. – Scipher Medicine, a precision immunology company, has announced a strategic partnership with a top-three global pharmaceutical company to integrate its PrismRA® diagnostic tool into an active clinical trial. The collaboration aims to refine clinical trial design by identifying which patients are unlikely to respond to specific therapies, helping improve patient selection and treatment outcomes.
PrismRA is Scipher’s proprietary precision medicine diagnostic that evaluates a patient’s molecular profile to predict non-response to certain drugs. Its integration into the trial will offer valuable insights into therapy response segmentation, allowing for better characterization of treatment effects across different patient subgroups. Scipher says this approach could help accelerate drug development while reducing risk.
“This collaboration exemplifies our commitment to embedding precision medicine into the drug development process,” said Scipher Medicine CEO Reg Seeto. “By using diagnostics like PrismRA, we can help partners better understand treatment response, design more efficient trials, and ultimately match the right therapies with the right patients.”
The partnership reflects the growing role of precision medicine tools in pharmaceutical research. Scipher’s broader capabilities include AI-based target selection, biomarker discovery, and a vast clinico-transcriptomic data resource, which the company uses to support innovation across drug development.
Terms of the agreement were not disclosed.
